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Tyrosine kinase is a key enzyme utilized in 
many intracellular messaging pathways. 
Understanding of the role of particular 
tyrosine kinases in various malignancies 
has allowed for the design of compounds, 
the tyrosine kinase inhibitors (TKIs).  TKIs 
have proven to be very successful in the 
treatment of a wide variety of malignant 
diseases including chronic myeloid leukemia 
(CML), Philadelphia chromosome positive 
acute lymphoblastic leukemia (ALL), renal 
cell carcinoma (RCC) and gastrointenstinal 
stromal tumors (GIST). Given the widespread 
nature of tyrosine kinase as a target and 
the promiscuous nature of the various 
inhibitors, it would not be surprising that 
these drugs would have effects beyond 
the expected result of targeting merely the 
tyrosine kinase of interest. Scattered reports 
have suggested that these agents appear to 
affect blood glucose levels [1-5]. References:
1.  Billemont B, Medioni J, Taillade L, et al.  Blood glucose 
levels in patients with metastatic renal cell carcinoma 
treated with sunitinib. Br J Cancer 2008 pp. 1-3.
2.  Veneri D, Franchini M, Bonora E. Imatinib and regression 
of type 2 diabetes.  NEJM 2005 352(10):1049-1050.
3.  Breccia M, Muscaritoli M, Aversa Z, et al.  Imatinib 
mesylate may improve fasting blood glucose in diabetic 
Ph+ chronic myelogenous leukemia patients responsive 
to treatment.  J Clin Oncology 2004 22(22):4653-5.
4.  Breccia M, Muscaritoli M, Cannella L, et al. Fasting 
glucose improvement under dasatinib treatment in 
accelerated phase chronic myeloid leukemia patient 
unresponsive to imatinib and nilotinib. Leukemia Res 
2008 32:1626-8.
5.  Haap M, Gallwitz B, Thamer C, et al.  Symptomatic 
hypoglycemia during imatinib mesylate in a non-diabetic 
female patient with gastrointestinal stromal tumor.  J 
Endocrin Inv 2007 30(8):688-92.
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 *One patient in this group overlapped in the diabetic imatinib group
**One patient in this group overlapped with the diabetic sorafenib group
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We studied the blood glucose (BG) 
concentrations on blood samples drawn 
before, during and after TKI therapy 
retrospectively in both diabetic (19) (all type 
II diabetes) and non-diabetic (61) patients 
treated with dasatinib (8), imatinib (39), 
sorafenib (23) and sunitinib (30) in general 
clinical practice.  Samples were mixed but 
most were daytime non-fasting.
Methods:
See Table 1 for demographic 
information.  All 4 drugs 
resulted in statistically 
significant decreased blood 
glucose levels in both diabetic 
and non-diabetic patients that 
resolved with cessation of 
treatment. Mean decreases 
blood glucose values for both 
non-diabetic and diabetic 
patients for dasatinib were – 53 
mg/dl (p<0.001), imatinib – 9 
mg/dl (p=0.03), sorafenib – 12 
mg/dl (p<0.001) and sunitinib -
14 mg/dl (p<0.001).  See Figure 
1.  Forty seven percent (8/17) 
of the patients with diabetes 
were able to discontinue 
their medications, including 
insulin in some patients. One 
diabetic patient developed 
symptomatic hypoglycemia 
on sunitinib.  See Table 2 for 
adjustments made to diabetic 
medications.
Results:
The mechanism for the hypoglycemic 
effect of these drugs is unclear, but of 
the 4 agents tested, c-kit is a common 
target.  C-kit has been shown to play a 
role in pancreatic β-cell survival in mouse 
models, so it is unclear why an inhibitor 
of the c-kit tyrosine kinase would improve 
blood glucose levels.  It is important 
for clinicians to keep the potentially 
hypoglycemic effects of these agents in 
mind, as symptomatic hypoglycemia can 
occur and modification of hypoglycemic 
agents may be required. These results 
also suggest that inhibition of a tyrosine 
kinase, be it c-kit or some other undefined 
target, may improve diabetes mellitus and 






Figure 1: Blood glucose levels before, 
during, and after treatment with a TKI 
(bars indicate standard error)
Table 1: Demographic Information
Patient # TKI
Diabetes meds before start of 




glyburide/metformin 5/1000  BID
glyburide/metformin 5/1000  BID




14 Imatinib insulin 70/30 25U Qam, 15U Qpm
metformin 500mg BID
glyburide/metformin 5/1000  BID
19 Imatinib none none
20 Imatinib glipizide XL (dose unknown) sitagliptin/metformin50/500BID
23 Imatinib none metformin 500mg BID
29 Imatinib glipizide 10mg Qdaily none
48 Sunitinib
Sorafenib
insulin (unknown dose)                        
insulin (unknown dose)                        
none
none
57 Sorafenib none none
60 Sorafenib metformin 500mg BID
rosiglitazone 4mg Qdaily
glipizide XL 10mg Qdaily
none
62 Sorafenib metformin (unknown dose) 
glipizide (unknown dose)                          
none
63 Sorafenib metformin 500mg BID
pioglitazone 30mg Qdaily
sitagliptin (unknown dose)
67 Sunitinib sitagliptin (unknown dose)
meformin (unknown dose)
none
69 Sunitinib insulin glargine (unknown dose)
Insulin aspart (unknown dose)
none
71 Sunitinib metformin 850mg BID 
glimepiride 4mg Qdaily
none
73 Sunitinib glimepiride 4mg Qdaily glipizide 5mg Qdaily
74 Sunitinib none none
80 Sunitinib insulin glargine (unknown dose)
insulin aspart (unknown dose)
none
Table 2: Diabetic medication changes made while on TKI
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